Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11270312 | 0.91 | GAA (0.74) | HDAC1HDAC6GAAPOLBKMT2A | |
| SCHEMBL8291943 | 0.88 | GAA (0.84) | HDAC1HDAC6GAAPOLBKMT2A | |
| SCHEMBL6641053 | 0.83 | GAA (0.63) | HDAC1HDAC6GAAPOLBKMT2A | |
| SCHEMBL15289687 | 0.82 | HDAC6 (1.00) | HDAC1HDAC6GAAPOLB | |
| SCHEMBL7495641 | 0.81 | GAA (0.52) | HDAC1HDAC6GAAPOLBKMT2A | |
| SCHEMBL7495637 | 0.81 | GAA (0.52) | HDAC1HDAC6GAAPOLBKMT2A | |
| SCHEMBL9453746 | 0.81 | HDAC1 (0.60) | HDAC1HDAC6GAAPOLBKMT2A | |
| SCHEMBL13879408 | 0.81 | HDAC6 (0.59) | HDAC1HDAC6GAAPOLBKMT2A | |
| SCHEMBL29721615 | 0.80 | HDAC1 (0.58) | HDAC1HDAC6GAAPOLBKMT2A | |
| SCHEMBL3494772 | 0.79 | HDAC6 (0.71) | HDAC1HDAC6GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | HDAC1 1389/4885HDAC6 1951/4885GAA 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.